サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：円錐角膜治療の世界市場-2023年～2030年
市場調査レポート
商品コード
1345394

円錐角膜治療の世界市場-2023年～2030年

Global Keratoconus Treatment Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
円錐角膜治療の世界市場-2023年～2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

世界の円錐角膜治療市場は2022年に5億米ドルに達し、2030年には6億米ドルに達すると予測され、予測期間（2023-2030年）のCAGRは3.9%です。

円錐角膜は、通常は丸い角膜が薄く凸凹した（円錐）形状になり、眼球を透過した光が網膜に正確に集中するのを妨げ、視力の歪みを引き起こす視力疾患です。通常、円錐角膜は両眼に現れ、視軸のすぐ下に円錐のピークを持つ中央角膜に影響を及ぼします。およそ10万人中50～200人が円錐角膜に罹患しています。

目に関連する問題の症例の増加、研究イニシアチブの増加、共同研究、製品承認、その他の研究活動などの市場開拓、技術進歩などが、予測期間中の円錐角膜治療の世界市場の成長を押し上げると予想されます。

ダイナミクス

新興国市場の開拓が円錐角膜治療市場の成長を牽引

新興国市場の開拓が、予測期間中の世界の円錐角膜治療市場の成長を後押しすると予想されます。例えば、2022年8月、角膜障害、緑内障、網膜障害の治療のための新規治療に注力している眼科医療技術および製薬企業であるグラウコス社は、非外科的、非侵襲的、薬理学的イノベーションを設計している非上場の臨床段階の眼科企業であるiVeena Delivery Systems社と戦略的ライセンス契約を締結し、グラウコス社に円錐角膜治療のためのIVMED-80の設計および商品化に関する唯一の世界な同意を与えました。

さらに、2023年7月、眼科医療製品会社であるボシュロムは、ジョンソン・エンド・ジョンソンの子会社であるジョンソン・エンド・ジョンソン・ビジョンから、OTC目薬「ブリンク」を1億650万米ドルで買収しました。この最新の買収は、OTCアイケアの開発で顧客の快適性を高めるという企業の確約に追加されます。

円錐角膜治療をサポートするイニシアチブの増加は、成長機会とともに世界の円錐角膜治療市場を提示すると予想されます。

円錐角膜治療を支援するイニシアチブの増加は、今後数年間で、世界の円錐角膜治療市場に有望な成長機会を提示すると期待されています。例えば、世界の円錐角膜教育イニシアチブは、円錐角膜eリソース-円錐角膜の現代的な管理への包括的なガイド、臨床における円錐角膜の識別と管理に関するウェビナーなど、診療で円錐角膜を治療するために必要なあらゆる情報を提供しています。

認識不足は予測期間中、世界の円錐角膜治療市場を阻害すると予測されます。

認知度の不足は、世界の円錐角膜治療市場の成長を妨げると予測されています。例えば、目に関連する多くの問題は、非常に徐々に成長し、過失のために誘発されます。これらの問題の中には、ごく小さなものもあれば、高額な特定の治療を必要とするものもあります。徹底的に発展している地域では、かなりの数の個人がこれらの症状の治療を選択するのに十分なお金を持っていません。また、患者の大多数は、病状の深刻化に対する十分な理解を持っていません。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 新興国市場の開拓
      • 研究の進展
    • 抑制要因
      • 認識不足
    • 機会
      • イニシアチブの増加
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 タイプ別

  • 角膜水腫
  • 不完全型円錐角膜
  • 後円錐角膜
  • 環状角膜
  • ペルーシド角膜変性

第8章 治療タイプ別

  • レンズ
  • 治療薬
  • 手術
  • その他

第9章 エンドユーザー別

  • 病院
  • 在宅医療
  • 専門クリニック
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Sandoz International GmbH
    • 企業概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な動向
  • HOYA
  • Menicon Co., Ltd.
  • The Cooper Companies, Inc.
  • Bausch Health Companies Inc.
  • SynergEyes
  • Carl Zeiss Meditec AG
  • Contamac
  • SEED Co., Ltd
  • Novartis AG
  • Johnson & Johnson Services, Inc.

第13章 付録

目次
Product Code: PH6756

Overview

The global Keratoconus Treatment market reached US$ 0.5 billion in 2022 and is expected to reach US$ 0.6 billion by 2030, exhibiting a CAGR of 3.9% during the forecast period (2023-2030).

Keratoconus is an eyesight condition that transpires when the commonly round cornea becomes thin and uneven (cone) shaped, preventing the light penetrating the eye from being concentrated accurately on the retina and causing contortion of vision. Usually, keratoconus appears in both eyes and affects the central cornea with the peak of the cone just under the visual axis. Roughly 50 to 200 of every 100,000 individuals are afflicted with keratoconus.

The growing cases of eye-related problems, increasing research initiatives, market developments such as collaborations, product approvals, and other; research activities, and technological advancements among other factors are expected to boost the global Keratoconus Treatment market growth in the forecast period.

Dynamics

Increasing Market Developments Drive the Growth of the Keratoconus Treatment Market.

Increasing market developments are expected to boost the global keratoconus treatment market growth in the forecast period. For instance, in August 2022, Glaukos, ophthalmic medical technology, and pharmaceutical corporation that concentrated on novel treatments for the therapy of corneal disorders, glaucoma, and retinal disorders constituted a strategic licensing contract with iVeena Delivery Systems, a privately held, clinical-stage ophthalmology corporation designing non-surgical, non-invasive, pharmacologic innovations giving Glaukos a sole global consent to design and commercialize IVMED-80 for the therapy of keratoconus.

Moreover, in July 2023, Bausch + Lomb, an eye health products corporation acquired the Blink over-the-counter (OTC) line of eye drops from Johnson & Johnson Vision, a subsidiary of Johnson & Johnson for the decided cost of USD 106.5 million. This most current acquisition adds to the corporation's affirmation to persist in increasing customer comfort with OTC eye care developments.

The Increasing initiatives to support the keratoconus treatment are Expected to Present the Global Keratoconus Treatment Market With Growth Opportunities.

The increasing initiatives to support the keratoconus treatment are expected to present the global keratoconus treatment market with prospective growth opportunities in the forthcoming years. For instance, the global Keratoconus Education Initiative provides you with everything you need to know to treat keratoconus in your practice including, the Keratoconus eResource- a comprehensive guide to the modern Management of Keratoconus, webinar on identifying and managing keratoconus in clinical practice.

The Lack of Awareness is Estimated to Hamper the Global Keratoconus Treatment Market During the Forecast Period.

The lack of awareness is estimated expected to hamper the global keratoconus treatment market growth. For instance, numerous eye-related issues grow very gradually and are induced because of negligence. Some of these concerns are tiniest, while some require certain therapies that are costly. In thoroughly evolving regions, a considerable number of individuals do not have sufficient money to opt for therapy for these conditions. Again, a majority of them have an insufficient understanding regarding such conditions that, additionally advance the harshness.

For more details on this report - Request for Sample

Segment Analysis

The global keratoconus treatment market is segmented based on type, treatment type, end-users, and region.

The Surgical Treatment Type Segment of Keratoconus Treatment is Estimated to Dominate the Global Keratoconus Treatment Market.

The surgical treatment type segment of the keratoconus treatment is expected to hold around 27.8% of the global market share owing to the increasing research activities. For instance, in January 2023, Glaukos, ophthalmic medical technology, and pharmaceutical corporation that concentrated on novel treatments for the therapy of corneal disorders, glaucoma, and retinal disorders declared the positive outcomes for a forthcoming, multi-center clinical investigation devised to assess the safeness of the surgical exchange approach for travoprost intraocular implant in individuals who had already obtained a travoprost intraocular implant in the Phase 2b clinical trial, also called the exchange trial.

Furthermore, the increasing initiatives in the surgical treatment type also contribute to segment growth. For instance, in April 2023, Michael W. Belin, MD, CMO of CXL Ophthalmics, Inc., a clinical-stage corporation designing a minimally invasive keratoconus therapy, is expected to provide the Plenary Session at the first International Keratoconus Academy (IKA) Symposium. The meeting is expected to get joint optometrists, ophthalmologists, and industry professionals curious about the administration and therapy of keratoconus.

Ggeographical Penetration

North America is estimated to hold Approximately 38.3% of the Market Share by 2030, Owing to Market Developments in this Region.

Owing to the increasing market developments in the North American region, it is estimated to dominate the global market holding around 38.3% of the market by 2030. For instance, For instance, in November 2022, CooperVision added SynergEyes to its CooperVision professional eye care industry segment, intensifying its promise to promote the usage of professional contact lenses in North America and almost the globe. The mixed lens approaches and trademarks presented by the Carlsbad, California-based corporation cover the therapy of uneven cornea, presbyopia, and astigmatism.

Furthermore, the increasing research activities on keratoconus also contribute to the regional market growth in the forecast period. For instance, the investigators at the North Texas Eye Research Institute recognized, separated, and characterized tear EVs (tEVs) in keratoconus patients and discovered that they have a different phenotype corresponding to their healthy counterparts. In the investigation, 10 healthy subjects and nine keratoconus-diagnosed individuals were analyzed. Men with eye disorders were also discovered to have more elevated total counts of tEVs than females.

Competitive Landscape

The major global players in the keratoconus treatment market include: Sandoz International GmbH, HOYA, Menicon Co., Ltd., The Cooper Companies, Inc., Bausch Health Companies Inc., SynergEyes, Carl Zeiss Meditec AG, Contamac, SEED Co., Ltd, Novartis AG, and Johnson & Johnson Services, Inc., among others.

COVID-19 Impact Analysis

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is assumed to have had a moderate impact on the global keratoconus treatment market, as during the 3 months of full-scale warfare, Russians sabotaged over 600 infirmaries and massacred at least 12 medics. Access to health care is majorly affected because of security considerations, limited mobility, damaged supply chains, and mass population eviction. Also, the lack of primary market players in this region. In addition to it, the significance of the import and export of fundamental materials are expected to slightly impact the global Keratoconus Treatment market growth in the forecast period.

By Type

  • Corneal Hydrops
  • Forme Fruste Keratoconus
  • Posterior Keratoconus
  • Keratoglobus
  • Pellucid Marginal Degeneration

By Treatment Type

  • Lenses
  • Therapies
  • Surgery
  • Others

By End-Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In May 2023, Menicon Co., Ltd. declared that Itabashi Medical (Dalian) Co., Ltd., a Chinese affiliate, launched "ROSE K" in China in April 2023. A hard contact lens for keratoconus individuals is called ROSE K.
  • In September 2022, CXL Ophthalmics, Inc., a clinical-stage corporation designing a minimally-invasive treatment for keratoconus, declared positive outcomes of the EpiSmart cross-linking Phase 2 study for keratoconus in Cornea.
  • In September 2022, CXL Ophthalmics, Inc., a clinical-stage corporation designing a minimally-invasive treatment for keratoconus, secured a $32 million Series A funding round led by AXA IM Alts through its Global Health Private Equity approach plus a syndicate of individual investors, including leading cornea specialists.

Why Purchase the Report?

  • To visualize the global keratoconus treatment market segmentation based on type, treatment type, end-users, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous keratoconus treatment market-level data points with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available in excel consisting of key products of all the major players.

The global keratoconus treatment market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Treatment Type
  • 3.3. Snippet by End-Users
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Market Developments
      • 4.1.1.2. Research Advancements
    • 4.1.2. Restraints
      • 4.1.2.1. Lack of Awareness
    • 4.1.3. Opportunity
      • 4.1.3.1. Increasing Initiatives
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Corneal Hydrops*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Forme Fruste Keratoconus
  • 7.4. Posterior Keratoconus
  • 7.5. Keratoglobus
  • 7.6. Pellucid Marginal Degeneration

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.1.2. Market Attractiveness Index, By Treatment Type
  • 8.2. Lenses*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Therapies
  • 8.4. Surgery
  • 8.5. Others

9. By End-Users

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
    • 9.1.2. Market Attractiveness Index, By End-Users
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Homecare
  • 9.4. Specialty Clinics
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Spain
      • 10.3.6.5. Italy
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan

Australia

      • 10.5.6.4. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Sandoz International GmbH*
    • 12.1.1. Company Overview
    • 12.1.2. Type Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. HOYA
  • 12.3. Menicon Co., Ltd.
  • 12.4. The Cooper Companies, Inc.
  • 12.5. Bausch Health Companies Inc.
  • 12.6. SynergEyes
  • 12.7. Carl Zeiss Meditec AG
  • 12.8. Contamac
  • 12.9. SEED Co., Ltd
  • 12.10. Novartis AG
  • 12.11. Johnson & Johnson Services, Inc.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Types
  • 13.2. Contact Us